137 related articles for article (PubMed ID: 22520478)
1. Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group.
Ausborn NL; Le QT; Bradley JD; Choy H; Dicker AP; Saha D; Simko J; Story MD; Torossian A; Lu B
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e453-64. PubMed ID: 22520478
[TBL] [Abstract][Full Text] [Related]
2. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
4. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer.
Kulesza P; Ramchandran K; Patel JD
Am J Clin Pathol; 2011 Aug; 136(2):228-38. PubMed ID: 21757595
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Reungwetwattana T; Weroha SJ; Molina JR
Clin Lung Cancer; 2012 Jul; 13(4):252-66. PubMed ID: 22154278
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
7. Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists.
Mazzone P; Mekhail T
Respir Med; 2012 Apr; 106(4):473-92. PubMed ID: 22119173
[TBL] [Abstract][Full Text] [Related]
8. The tissue is the issue: personalized medicine for non-small cell lung cancer.
Hirsch FR; Wynes MW; Gandara DR; Bunn PA
Clin Cancer Res; 2010 Oct; 16(20):4909-11. PubMed ID: 20926402
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
13. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
Pérez-Soler R
Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
[TBL] [Abstract][Full Text] [Related]
14. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
15. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
[TBL] [Abstract][Full Text] [Related]
16. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
Cooper WA; O'toole S; Boyer M; Horvath L; Mahar A
Pathology; 2011 Feb; 43(2):103-15. PubMed ID: 21233671
[TBL] [Abstract][Full Text] [Related]
17. New agents in advanced non-small-cell lung cancer treatment.
Ricciardi S; de Marinis F
Oncology; 2009; 77 Suppl 1():103-12. PubMed ID: 20130438
[TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of response to chemotherapy in non-small cell lung cancer.
Andrews J; Yeh P; Pao W; Horn L
Cancer J; 2011; 17(2):104-13. PubMed ID: 21427554
[TBL] [Abstract][Full Text] [Related]
19. Translational research in lung cancer.
Chen Y; Okunieff P; Ahrendt SA
Semin Surg Oncol; 2003; 21(3):205-19. PubMed ID: 14508854
[TBL] [Abstract][Full Text] [Related]
20. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
Hirsch FR
Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
